David Beckham’s IM8 Health debuts longevity supplement targeting 12 hallmarks of aging

IM8 Health, co-founded by David Beckham and backed by Prenetics, unveils its latest longevity solution — Daily Ultimate Longevity. Developed in partnership with scientists from the Mayo Clinic and the former Chief Scientist of NASA, the formula leverages IM8’s proprietary 5-Complex System to address the biological roots of aging.

According to the company, the offering is the first nutritional supplement scientifically formulated to target the 12 “hallmarks of aging” — a framework defined by researchers in the journal Cell.

“We created the most advanced longevity supplement on the market, featuring key ingredients like high-dose glycine and taurine, powerful senolytic compounds including quercetin and fisetin, nicotinamide adenine dinucleotide (NAD+) boosters nicotinamide mononucleotide (NMN) and pyrroloquinoline quinone (PQQ), plus metabolic enhancers like dihydroberberine,” explains Dr. Darshan Shah, a board certified surgeon and physician and scientific advisory board member at IM8.

“The five synergistic complexes of the new advanced Daily Ultimate Longevity target cellular senescence, one of the primary hallmarks of aging, while promoting comprehensive cellular energy support and DNA repair.”

Longevity boosting formulation

The company spotlights that each complex — from cellular foundation and protection to energy, metabolic, and renewal activation — delivers evidence-backed doses of functional compounds such as resveratrol and spermidine. IM8 emphasizes that these ingredients support cellular function, strengthen mitochondrial health, and promote natural repair pathways associated with longevity and vitality.

Moreover, Daily Ultimate Longevity’s powder format is convenient, while allowing for increased active ingredient capacity. The offering is also designed to be stacked with IM8’s Daily Ultimate Essentials and completes what the brand calls the “Enhanced Beckham Stack” — a two-part daily supplement.

“We’re not just launching a product — we’re defining an entirely new category in longevity science,” Danny Yeung, the CEO and co-founder of Prenetics and IM8, underscores. 

Longevity market traction

Since its full launch in December 2024, IM8 reveals it has scaled from roughly US$600,000 to US$6.6 million in monthly revenue and delivered more than 10 million servings to over 350,000 customers. The company also projects US$100 million in annual recurring revenue within its first year and says it is poised to lead in the growing global longevity market.

“As we approach our unprecedented US$100 million annual recurring revenue milestone within our first year, this breakthrough formulation demonstrates why IM8 has achieved growth rates that are virtually unheard of in the industry,” Yeung concludes.